Intelligence · Clinical Development
Pipeline search results
Programs matching “protocol” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 21 pipeline programs matching "protocol" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
RBC transfusion based on different protocols
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Transfusion Related Complication
1 trial -
TARGET protocol EN 1.5 kcal/mL
Zealand Pharma A/S
Critical Illness
1 trial -
Tecentriq 1 200 mg concentrate for solution for infusion
Hoffmann-La Roche
Cancer (Future parent protocols may include other cancer that are not included in this section)
1 trial -
Unified protocol for adolescents (UP-A)
Chinese University of Hong Kong
Depressive Disorder
1 trial -
2022/3418 INDIGO
The George Institute
Adult patients with a histologically confirmed TLS-positive advanced or metastatic NSCLC naïve from systemic treatment or previously treated with chemotherapy and PD1/PDL1 antagonist, and not having previously been treated with CD137 agonists or investigational immune checkpoint blockade therapies, including (but not limited) anti-TIGIT, anti-LAG3. Patients must have adequate organ function with a performance status (WHO 0-1; ECOG 0-1). Patients must not have active or history of autoimmune disease or immune deficiency. The pregnant or breastfeeding women will be excluded. Other eligibility criteria are described in the related section of the protocol.
1 trial -
BZD discontinuation protocol
BRIGHT MINDS BIOSCIENCES INC.
Substance Use Disorders
1 trial -
NKTR-214
Nektar Therapeutics UK Limited
Unspecified Adult Solid Tumor, Protocol Specific
1 trial -
Protocol number 8
The George Institute
Glioblstoma WHO grade IV
1 trial -
Rilvegostomig, Rilvegostomig
AstraZeneca AB
Advanced Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer, stage III unresectable Non-small Cell Lung Cancer (Protocol Parts A-B), stage IV Non-small Cell Lung Cancer (Protocol Parts A-E).
1 trial -
The Modular Protocol for Mental Health
COGNITION THERAPEUTICS INC
Major Depressive Disorder
1 trial -
Varenicline Adaptive Protocol
BRIGHT MINDS BIOSCIENCES INC.
Nicotine Dependence
1 trial -
BEZ235 + MEK162
Pfizer
Unspecified Adult Solid Tumor, Protocol Specific
1 trial -
DS3201-324
Daiichi Sankyo
This study will be a Phase 1b, global, multicenter, open-label, 2-part study of valemetostat in combination with DXd ADCs. The Master Protocol study design contains independent subprotocols, which have been defined by treatment combination and subject population, as follows: Sub-protocol A: Valemetostat in combination with T-DXd in subjects with previously treated, unresectable and/or metastatic HER2-low (immunohistochemistry[IHC] 1+ or IHC 2+/in situ hybridization [ISH]-negative) BC; for details, see Sub-protocol A. Sub-protocol B: Valemetostat in combination with T-DXd in subjects with previously treated, advanced or metastatic HER2-positive gastric or GEJ adenocarcinoma; for details, see Sub-protocol B. Sub-protocol C: Valemetostat in combination with Dato-DXd in subjects with previously treated, locally advanced, unresectable, or metastatic non-squamous NSCLC with or without actionable genomic alteration(s); for details, see Sub-protocol C.
1 trial -
idronoxil
KAZIA THERAPEUTICS LTD
Unspecified Adult Solid Tumor, Protocol Specific
1 trial -
A8081075
Pfizer Australia Pty Ltd
This Master Protocol for Crizotinib Continuation Sub-Studies has been designed to provide continued treatment access for eligible participants who continue to derive clinical benefit from study intervention in a Pfizer sponsored crizotinib parent study that will be closed
1 trial -
CINC424A2X01B
Novartis Pharmaceuticals
This study is designed to accept patients with varied disease origins, depending on the parent protocol
1 trial -
DR230314
Tour Hekla
Evaluation of the CKD-Epi score to identify a glomerular filtration threshold predictive of morphine failure at usual dosage, using a reference method for assessing renal function: iohexol clearance. All other aspects of the protocol are part of standard care practice.
1 trial -
Protocol-based management of perioperative antithrombotic therapy
Peking University Third Hospital
Antithrombotic Therapy
1 trial -
Protocol-based management of perioperative antithrombotic therapy
The First People's Hospital of Lianyungang
Antithrombotic Therapy
1 trial -
Thermal stress and performance without a pre-cooling protocol
Petros Pharmaceuticals
Risk of Heat Stress
1 trial -
white wine
United Therapeutics Europe Ltd
Unspecified Adult Solid Tumor, Protocol Specific
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.